“Most people would agree that for xenotransplantation to become a reality, we’re going to need to use an anti-CD40L antibody ...

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...